Deneysel Şizofreni Modelleri
Özet
Şizofreni, dünya genelinde milyonlarca insanı etkileyen ve karmaşık etiyolojisi nedeniyle araştırılması güç olan ciddi bir nöropsikiyatrik bozukluktur. Hastalığın genetik, çevresel ve nörogelişimsel faktörlerin etkileşimiyle ortaya çıkması, patofizyolojik mekanizmaların çözülmesini zorlaştırmakta ve biyolojik belirteç eksikliği tanıyı güçleştirmektedir. Bu nedenle deneysel hayvan modelleri, şizofreninin altında yatan nörobiyolojik süreçlerin anlaşılması ve yeni tedavi yaklaşımlarının geliştirilmesi için kritik bir araç haline gelmiştir. Ancak insan zihnine özgü bilişsel ve duygusal süreçlerin tam olarak modellenememesi önemli bir sınırlılık oluşturmaktadır. Güncel araştırmalar, prefrontal korteks ve hipokampus gibi temel beyin bölgelerindeki işlevsel bozuklukların hayvanlarda çeşitli yöntemlerle taklit edilmesi üzerine yoğunlaşmaktadır. Şizofreni modellemesinde üç temel yaklaşım öne çıkmaktadır: transgenik, farmakolojik ve nörogelişimsel modeller. Bu bölümde, söz konusu modellerin kuramsal temelleri, deneysel uygulamaları, translasyonel geçerliliği ve her birinin avantaj ile sınırlılıkları bütüncül bir bakış açısıyla ele alınmaktadır. Amaç, araştırmacılara şizofreni patofizyolojisini anlamada ve terapötik stratejiler geliştirmede kullanılabilecek kapsamlı, metodolojik bir rehber sunmaktır.
Schizophrenia is a severe neuropsychiatric disorder affecting millions worldwide, characterized by complex interactions of genetic, environmental, and neurodevelopmental factors. The absence of definitive biological markers and the multifaceted nature of its symptoms make both diagnosis and mechanistic investigation challenging. Consequently, experimental animal models have become indispensable tools for exploring the underlying neurobiological pathways of the disorder and for developing novel therapeutic strategies. Despite inherent limitations—particularly the difficulty of replicating human-specific cognitive and emotional processes—recent advances have enabled the modeling of dysfunctions in key brain regions such as the prefrontal cortex and hippocampus. Current experimental approaches fall into three major categories: transgenic, pharmacological, and neurodevelopmental models. Each provides unique strengths and constraints depending on the aspect of pathology being examined. This chapter presents an integrated overview of these experimental models, detailing their theoretical rationale, methodological applications, translational relevance, and practical limitations. The aim is to offer researchers a concise yet comprehensive guide to selecting and implementing appropriate animal models for advancing our understanding of schizophrenia pathophysiology and supporting the development of effective treatments.
Referanslar
Tomasik J, Rahmoune H, Guest PC, Bahn S. Neuroimmune biomarkers in schizophrenia. Schizophrenia Research. 2016 Sep 1;176(1):3–13.
Solmi M, Seitidis G, Mavridis D, Correll CU, Dragioti E, Guimond S, et al. Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Mol Psychiatry. 2023 Dec;28(12):5319–27.
Bueno-Antequera J, Munguía-Izquierdo D. Exercise and Schizophrenia. Adv Exp Med Biol. 2020;1228:317–32.
Keshavan MS, Collin G, Guimond S, Kelly S, Prasad KM, Lizano P. Neuroimaging in schizophrenia. Neuroimaging Clin N Am. 2020 Feb;30(1):73–83.
Mueser KT, McGurk SR. Schizophrenia. The Lancet. 2004 Jun 19;363(9426):2063–72.
Wykes T, Haro JM, Belli SR, Obradors-Tarrago C, Arango C, Ayuso-Mateos JL, et al. Mental health research priorities for Europe. Lancet Psychiatry. 2015 Nov;2(11):1036–42.
Białoń M, Wąsik A. Advantages and Limitations of Animal Schizophrenia Models. Int J Mol Sci. 2022 May 25;23(11):5968.
Winship IR, Dursun SM, Baker GB, Balista PA, Kandratavicius L, Maia-de-Oliveira JP, et al. An Overview of Animal Models Related to Schizophrenia. Can J Psychiatry. 2019 Jan;64(1):5–17.
Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine Receptors: From Structure to Function. Physiological Reviews. 1998 Jan;78(1):189–225.
Tahiri J, Mian M, Aftan F, Habbal S, Salehi F, Reddy PH, et al. Serotonin in depression and Alzheimer’s disease: Focus on SSRI’s beneficial effects. Ageing Research Reviews. 2024 Nov 1;101:102537.
Dean B, Copolov D, Scarr E. Understanding the pathophysiology of schizophrenia: Contributions from the Melbourne Psychiatric Brain Bank. Schizophrenia Research. 2016 Nov 1;177(1):108–14.
Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiatry and Clinical Neurosciences. 2019;73(5):204–15.
Sweet RA, Henteleff RA, Zhang W, Sampson AR, Lewis DA. Reduced Dendritic Spine Density In Auditory Cortex Of Subjects With Schizophrenia. Neuropsychopharmacology. 2009 Jan;34(2):374–89.
Kruse AO, Bustillo JR. Glutamatergic dysfunction in Schizophrenia. Transl Psychiatry. 2022 Dec 3;12(1):500.
Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012 [cited 2026 Jan 21]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK61999/
Nehme R, Pietiläinen O, Artomov M, Tegtmeyer M, Valakh V, Lehtonen L, et al. The 22q11.2 region regulates presynaptic gene-products linked to schizophrenia. Nat Commun. 2022 Jun 27;13(1):3690.
Jaaro-Peled H, Sawa A. Neurodevelopmental Factors in Schizophrenia. Psychiatric Clinics of North America. 2020 Jun 1;43(2):263–74.
Brown AS. The environment and susceptibility to schizophrenia. Progress in Neurobiology. 2011 Jan 1;93(1):23–58.
Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry. 2002 Jul;159(7):1080–92.
Susser E, St Clair D. Prenatal famine and adult mental illness: Interpreting concordant and discordant results from the Dutch and Chinese Famines. Social Science & Medicine. 2013 Nov 1;97:325–30.
Ellenbroek BA, Cools AR. Animal models with construct validity for schizophrenia. Behavioural Pharmacology. 1990 Winter;1(6):469.
Jones C, Watson D, Fone K. Animal models of schizophrenia. Br J Pharmacol. 2011 Oct;164(4):1162–94.
Steeds H, Carhart-Harris RL, Stone JM. Drug models of schizophrenia. Therapeutic Advances in Psychopharmacology. 2015 Feb 1;5(1):43–58.
Carpenter WT, Koenig JI. The Evolution of Drug Development in Schizophrenia. Neuropsychopharmacology. 2008 Aug;33(9):2061–79.
Crunfli F, Brandão Teles C, Zuccoli G, Chaves-Filho A, Vieira G, Silva-Amaral D, et al. What Can We Learn from Animal Models to Study Schizophrenia? In: Advances in experimental medicine and biology. 2022. p. 15–33.
Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, et al. Comparison of Ketamine-Induced Thought Disorder in Healthy Volunteers and Thought Disorder in Schizophrenia. AJP. 1999 Oct;156(10):1646–9.
Verma A, Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci. 1996 Jan;16(1):373–9.
O’Donnell P, Grace AA. Phencyclidine interferes with the hippocampal gating of nucleus accumbens neuronal activity in vivo. Neuroscience. 1998 Dec;87(4):823–30.
Yavas E, Young AMJ. Repeated phencyclidine disrupts nicotinic acetylcholine regulation of dopamine release in nucleus accumbens: Implications for models of schizophrenia. Neurochemistry International. 2020 Nov 1;140:104836.
Murase S, Mathé JM, Grenhoff J, Svensson TH. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization. J Neural Transm Gen Sect. 1993;91(1):13–25.
Mathé JM, Nomikos GG, Schilström B, Svensson TH. Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J Neurosci Res. 1998 Mar 1;51(5):583–92.
Jentsch JD, Taylor JR, Roth RH. Subchronic Phencyclidine Administration Increases Mesolimbic Dopaminergic System Responsivity and Augments Stress- and Psychostimulant-Induced Hyperlocomotion. Neuropsychopharmacol. 1998 Aug;19(2):105–13.
Phillips M, Wang C, Johnson KM. Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. J Pharmacol Exp Ther. 2001 Mar;296(3):905–13.
Rowland LM. Subanesthetic ketamine: how it alters physiology and behavior in humans. Aviat Space Environ Med. 2005 Jul;76(7 Suppl):C52-58.
Krystal JH, Perry EB Jr, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, et al. Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine: Implications for Glutamatergic and Dopaminergic Model Psychoses and Cognitive Function. Archives of General Psychiatry. 2005 Sep 1;62(9):985–95.
Stone JM, Pilowsky LS. Psychopathological consequences of ketamine. The British Journal of Psychiatry. 2006 Dec;189(6):565–6.
Stone JM, Erlandsson K, Arstad E, Squassante L, Teneggi V, Bressan RA, et al. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy—a [123I]CNS-1261 SPET study. Psychopharmacology. 2008 Apr 1;197(3):401–8.
Canever L, Freire TG, Mastella GA, Damázio L, Gomes S, Fachim I, et al. Changes in behavioural parameters, oxidative stress and neurotrophins in the brain of adult offspring induced to an animal model of schizophrenia: The effects of FA deficient or FA supplemented diet during the neurodevelopmental phase. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2018 Aug 30;86:52–64.
Akcay G. Therapeutic effects of transcranial direct current stimulation on ketamine-induced schizophrenia-like behaviors and oxidative stress. Medicine Science. 2023 Mar 1;12(1):63.
Robinson TE, Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J Neurosci. 1997 Nov 1;17(21):8491–7.
Martinez V, Parikh V, Sarter M. Sensitized attentional performance and Fos-immunoreactive cholinergic neurons in the basal forebrain of amphetamine-pretreated rats. Biol Psychiatry. 2005 May 15;57(10):1138–46.
El-Sayed El-Sisi A, Sokkar SS, El-Sayed El-Sayad M, Sayed Ramadan E, Osman EY. Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia. Biomed Pharmacother. 2016 Aug;82:425–31.
Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Research Reviews. 2000 Mar 1;31(2):302–12.
Canal CE, Morgan D. Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. Drug Test Anal. 2012;4(7–8):556–76.
Rajji TK, Ismail Z, Mulsant BH. Age at onset and cognition in schizophrenia: meta-analysis. The British Journal of Psychiatry. 2009 Oct;195(4):286–93.
Gregg JR, Herring NR, Naydenov AV, Hanlin RP, Konradi C. Downregulation of oligodendrocyte transcripts is associated with impaired prefrontal cortex function in rats. Schizophrenia Research. 2009 Sep 1;113(2):277–87.
Herring NR, Konradi C. MYELIN, COPPER, AND THE CUPRIZONE MODEL OF SCHIZOPHRENIA. Front Biosci (Schol Ed). 2011 Jan 1;3:23–40.
Makinodan M, Yamauchi T, Tatsumi K, Okuda H, Takeda T, Kiuchi K, et al. Demyelination in the juvenile period, but not in adulthood, leads to long-lasting cognitive impairment and deficient social interaction in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2009 Aug 31;33(6):978–85.
Zirngibl M, Assinck P, Sizov A, Caprariello AV, Plemel JR. Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination. Mol Neurodegener. 2022 May 7;17(1):34.
Feigenson KA, Kusnecov AW, Silverstein SM. Inflammation and the Two-Hit Hypothesis of Schizophrenia. Neurosci Biobehav Rev. 2014 Jan;38:72–93.
Machado CJ, Whitaker AM, Smith SEP, Patterson PH, Bauman MD. Maternal immune activation in nonhuman primates alters social attention in juvenile offspring. Biol Psychiatry. 2015 May 1;77(9):823–32.
Meyer U. Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry. 2014 Feb 15;75(4):307–15.
Cattabeni F, Di Luca M. Developmental models of brain dysfunctions induced by targeted cellular ablations with methylazoxymethanol. Physiol Rev. 1997 Jan;77(1):199–215.
Matsumoto H, Higa HH. Studies on methylazoxymethanol, the aglycone of cycasin: methylation of nucleic acids in vitro. Biochem J. 1966 Feb;98(2):20C-22C.
Gomes FV, Rincón-Cortés M, Grace AA. Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM Model. Neurosci Biobehav Rev. 2016 Nov;70:260–70.
Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry. 2006 Aug 1;60(3):253–64.
Flagstad P, Mørk A, Glenthøj BY, van Beek J, Michael-Titus AT, Didriksen M. Disruption of Neurogenesis on Gestational Day 17 in the Rat Causes Behavioral Changes Relevant to Positive and Negative Schizophrenia Symptoms and Alters Amphetamine-Induced Dopamine Release in Nucleus Accumbens. Neuropsychopharmacol. 2004 Nov;29(11):2052–64.
Brady AM. The Neonatal Ventral Hippocampal Lesion (NVHL) Rodent Model of Schizophrenia. Curr Protoc Neurosci. 2016 Oct 3;77:9.55.1-9.55.17.
Flores G, Alquicer G, Silva-Gómez AB, Zaldivar G, Stewart J, Quirion R, et al. Alterations in dendritic morphology of prefrontal cortical and nucleus accumbens neurons in post-pubertal rats after neonatal excitotoxic lesions of the ventral hippocampus. Neuroscience. 2005;133(2):463–70.
Ashe PC, Chlan-Fourney J, Juorio AV, Li XM. Brain-derived neurotrophic factor (BDNF) mRNA in rats with neonatal ibotenic acid lesions of the ventral hippocampus. Brain Res. 2002 Nov 22;956(1):126–35.
Maria E, Bringas Tobón M, Morales Medina JC, Flores-Vivaldo Y, Díaz JV, Aguilar-Alonso P, et al. Clozapine administration reverses behavioral, neuronal, and nitric oxide disturbances in the neonatal ventral hippocampus rat. Vol. 62, Neuropharmacology. 2012.
Joseph AT, Bhardwaj SK, Srivastava LK. Role of Prefrontal Cortex Anti- and Pro-inflammatory Cytokines in the Development of Abnormal Behaviors Induced by Disconnection of the Ventral Hippocampus in Neonate Rats. Front Behav Neurosci. 2018;12:244.
Tripathi A, Kar SK, Shukla R. Cognitive Deficits in Schizophrenia: Understanding the Biological Correlates and Remediation Strategies. Clin Psychopharmacol Neurosci. 2018 Feb 28;16(1):7–17.
Lee FHF, Fadel MP, Preston-Maher K, Cordes SP, Clapcote SJ, Price DJ, et al. Disc1 point mutations in mice affect development of the cerebral cortex. J Neurosci. 2011 Mar 2;31(9):3197–206.
Morosawa S, Iritani S, Fujishiro H, Sekiguchi H, Torii Y, Habuchi C, et al. Neuropeptide Y neuronal network dysfunction in the frontal lobe of a genetic mouse model of schizophrenia. Neuropeptides. 2017 Apr;62:27–35.
Umeda K, Iritani S, Fujishiro H, Sekiguchi H, Torii Y, Habuchi C, et al. Immunohistochemical evaluation of the GABAergic neuronal system in the prefrontal cortex of a DISC1 knockout mouse model of schizophrenia. Synapse (New York, NY). 2016 Dec 1;70(12):508–18.
Niwa M, Kamiya A, Murai R, Kubo K ichiro, Gruber AJ, Tomita K, et al. Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. Neuron. 2010 Feb 25;65(4):480–9.
Karayiorgou M, Simon TJ, Gogos JA. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci. 2010 Jun;11(6):402–16.
Qin X, Chen J, Zhou T. 22q11.2 deletion syndrome and schizophrenia. Acta Biochim Biophys Sin (Shanghai). 2020 Dec 11;52(11):1181–90.
Sun Z, Williams DJ, Xu B, Gogos JA. Altered function and maturation of primary cortical neurons from a 22q11.2 deletion mouse model of schizophrenia. Transl Psychiatry. 2018 Apr 18;8(1):1–14.
Piskorowski RA, Nasrallah K, Diamantopoulou A, Mukai J, Hassan SI, Siegelbaum SA, et al. Age-dependent specific changes in area CA2 of the hippocampus and social memory deficit in a mouse model of the 22q11.2 deletion syndrome. Neuron. 2016 Jan 6;89(1):163–76.
Wang H, Xu J, Lazarovici P, Zheng W. Dysbindin-1 Involvement in the Etiology of Schizophrenia. Int J Mol Sci. 2017 Sep 22;18(10):2044.
Ito H, Morishita R, Shinoda T, Iwamoto I, Sudo K, Okamoto K, et al. Dysbindin-1, WAVE2 and Abi-1 form a complex that regulates dendritic spine formation. Mol Psychiatry. 2010 Oct;15(10):976–86.
Trantham-Davidson H, Lavin A. Loss of dysbindin-1 affects GABAergic Transmission in the PFC. Psychopharmacology (Berl). 2019 Nov;236(11):3291–300.
Engel M, Snikeris P, Jenner A, Karl T, Huang XF, Frank E. Neuregulin 1 Prevents Phencyclidine-Induced Behavioral Impairments and Disruptions to GABAergic Signaling in Mice. Int J Neuropsychopharmacol. 2015 May;18(7):pyu114.
Suárez-Pinilla P, Roíz-Santiañez R, Mata I, Ortiz-García de la Foz V, Brambilla P, Fañanas L, et al. Progressive Structural Brain Changes and NRG1 Gene Variants in First-Episode Nonaffective Psychosis. Neuropsychobiology. 2015;71(2):103–11.
Deng C, Pan B, Engel M, Huang XF. Neuregulin-1 signalling and antipsychotic treatment. Psychopharmacology. 2013 Mar 1;226(2):201–15.
Chong VZ, Thompson M, Beltaifa S, Webster MJ, Law AJ, Weickert CS. Elevated Neuregulin-1 and ErbB4 Protein in the Prefrontal Cortex of Schizophrenic Patients. Schizophr Res. 2008 Mar;100(1–3):270–80.
Fone KCF, Porkess MV. Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci Biobehav Rev. 2008 Aug;32(6):1087–102.
Fabricius K, Helboe L, Fink-Jensen A, Wörtwein G, Steiniger-Brach B. Pharmacological characterization of social isolation-induced hyperactivity. Psychopharmacology (Berl). 2011 May;215(2):257–66.
Powell SB, Swerdlow NR. The Relevance of Animal Models of Social Isolation and Social Motivation for Understanding Schizophrenia: Review and Future Directions. Schizophrenia Bulletin. 2023 Sep 1;49(5):1112–26.
